 Interferon-gamma
"Interferon-gamma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
| Descriptor ID |
D007371
|
| MeSH Number(s) |
D12.644.276.374.440.893 D12.644.276.374.480.350 D12.644.276.374.480.615.350 D12.644.276.718.550 D12.776.467.374.440.893 D12.776.467.374.480.350 D12.776.467.374.480.615.350 D12.776.467.718.550 D23.529.374.440.893 D23.529.374.480.350 D23.529.374.480.615.350 D23.529.718.550
|
| Concept/Terms |
Interferon-gamma- Interferon-gamma
- Type II Interferon
- Interferon, Type II
- Interferon, gamma
- Interferon, Immune
- Immune Interferon
- gamma-Interferon
- Interferon Type II
|
Below are MeSH descriptors whose meaning is more general than "Interferon-gamma".
Below are MeSH descriptors whose meaning is more specific than "Interferon-gamma".
This graph shows the total number of publications written about "Interferon-gamma" by people in this website by year, and whether "Interferon-gamma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 1 | 1 | 2 | | 1987 | 3 | 3 | 6 | | 1988 | 5 | 3 | 8 | | 1989 | 5 | 4 | 9 | | 1990 | 3 | 3 | 6 | | 1991 | 2 | 3 | 5 | | 1992 | 3 | 4 | 7 | | 1993 | 3 | 6 | 9 | | 1994 | 3 | 4 | 7 | | 1995 | 6 | 4 | 10 | | 1996 | 2 | 4 | 6 | | 1997 | 2 | 6 | 8 | | 1998 | 6 | 5 | 11 | | 1999 | 2 | 8 | 10 | | 2000 | 3 | 2 | 5 | | 2001 | 7 | 6 | 13 | | 2002 | 3 | 10 | 13 | | 2003 | 4 | 6 | 10 | | 2004 | 5 | 14 | 19 | | 2005 | 3 | 7 | 10 | | 2006 | 2 | 11 | 13 | | 2007 | 5 | 10 | 15 | | 2008 | 8 | 9 | 17 | | 2009 | 1 | 9 | 10 | | 2010 | 1 | 9 | 10 | | 2011 | 7 | 8 | 15 | | 2012 | 3 | 11 | 14 | | 2013 | 1 | 8 | 9 | | 2014 | 2 | 9 | 11 | | 2015 | 2 | 4 | 6 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 4 | 5 | | 2018 | 1 | 4 | 5 | | 2019 | 1 | 5 | 6 | | 2020 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-gamma" by people in Profiles.
-
Choi JW, Withers SS, Chang H, Spanier JA, De La Trinidad VL, Panesar H, Fife BT, Sciammas R, Sparger EE, Moore PF, Kent MS, Rebhun RB, McSorley SJ. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 2020; 15(7):e0235518.
-
Alegre ML. Liver Protection by ILC1s. Am J Transplant. 2020 05; 20(5):1215.
-
Abadie V, Kim SM, Lejeune T, Palanski BA, Ernest JD, Tastet O, Voisine J, Discepolo V, Marietta EV, Hawash MBF, Ciszewski C, Bouziat R, Panigrahi K, Horwath I, Zurenski MA, Lawrence I, Dumaine A, Yotova V, Grenier JC, Murray JA, Khosla C, Barreiro LB, Jabri B. IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. Nature. 2020 02; 578(7796):600-604.
-
Williams JB, Li S, Higgs EF, Cabanov A, Wang X, Huang H, Gajewski TF. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells. Nat Commun. 2020 01 30; 11(1):602.
-
Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2020 02 15; 26(4):846-854.
-
Huang R, Wu J, Zhou X, Jiang H, Guoying Zhou G, Roizman B. Herpes Simplex Virus 1 MicroRNA miR-H28 Exported to Uninfected Cells in Exosomes Restricts Cell-to-Cell Virus Spread by Inducing Gamma Interferon mRNA. J Virol. 2019 11 01; 93(21).
-
Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
-
Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
-
Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK. Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. Neurosurgery. 2019 04 01; 84(4):945-953.
-
Botelho NK, Tschumi BO, Hubbell JA, Swartz MA, Donda A, Romero P. Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control. Front Immunol. 2019; 10:294.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|